Prescription Medicines
UrimoQ Tab. 0.1mg
- Product Category
- nocturia treatment
- Active Ingredients
- Desmopressin acetate
- Appearance
- A white, oval tablet.
- Reimbursement Code
- 648104470
01 / 02
1. Ingredient content
1 tablet
- Active ingredients:
Desmopressin acetate (EP) ----- 0.1mg
(0.089mg as desmopressin)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: magnesium stearate, corn starch, povidone
2. Effectiveness
Treatment of primary enuresis (age 5 or older) and nocturia related to nocturia (limited to adults)
3. Dosage and dosage
Primary enuresis (age 5 or older): Administer 0.2 mg orally as desmopressin acetate at bedtime. If the effect is not sufficient, the dose can be increased up to 0.4mg. The continuation of treatment is determined after stopping administration for at least 1 week after 3 months of administration.
Treatment of nocturia symptoms related to nocturnal polyuria (adults only): Orally administer 0.1 mg of desmopressin acetate at bedtime. If the effect is not sufficient after a week, the dose can be increased to 0.2mg. If the effect continues to be insufficient, the dose can be increased at weekly intervals up to 0.4mg.
If there is no clinical effect within 4 weeks after determining the dose, discontinue administration.
For patients over 65 years of age, it is not recommended to begin treatment with this drug, and for elderly patients requiring treatment, serum sodium levels, etc. should be closely monitored. (Refer to 5. General precautions among the precautions for use)
4. Precautions for use
1. Warning
In the following and elderly people, hyponatremia and water intoxication can cause coma, so to prevent this, be careful to drink just enough water to quench your thirst.
2. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or its ingredients
2) Patients with habitual and psychological polydipsia (if urine volume exceeds 40mL/kg in 24 hours)
3) Patients with dysfunctional heart failure
4) Patients taking diuretics
5) Patients with nephrogenic diabetes insipidus
6) This drug is administered only to patients with normal blood pressure when treating enuresis.
7) Patients with moderate and severe renal failure (creatinine clearance less than 50ml/min)
8) Antidiuretic hormone hypersecretion syndrome (SIADH)
9) Patients diagnosed with hyponatremia
10) This drug contains lactose, so galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
It should not be administered to patients with genetic problems such as (glucose-galactose malabsorption).
3. Administer with caution to the following patients.
1) Patients with circulatory disease accompanied by high blood pressure, severe arteriosclerosis, or coronary thrombosis (this may increase blood pressure and worsen symptoms)
2) Patients with chronic kidney disease
3) Pregnant women or women who may be pregnant
4) Children and elderly people
5) Patients with diseases that cause water and electrolyte imbalance and patients at risk of increased intracranial pressure
6) Patients with diseases related to water and electrolyte imbalance, such as cystic fibrosis (can cause hyponatremia)
7) For patients with urge incontinence, increased urinating frequency or nocturia due to organic causes (e.g. benign prostatic hyperplasia (BPH), urinary tract infection, bladder stones/tumor), polydipsia, and uncontrolled diabetes, the underlying disease should be treated.
4. Adverse reactions
1) In particular, severe water intoxication and hyponatremia accompanied by coma, convulsions, and weight gain may occur in the following and elderly patients.
2) Side effects reported in enuresis patients are as follows: allergic reaction, hyponatremia, emotional disturbance, headache, abdominal pain, nausea, and allergic skin reaction.
3) In clinical trials on patients with nocturia, 35% of patients who reported side effects showed side effects during dose adjustment, and the side effects reported were as follows: hyponatremia, headache, dizziness, peripheral edema, frequent urination, abdominal pain, nausea, dry mouth, and weight gain.
4) Side effects reported from the ingredients of this medicine are as follows: Anaphylaxis
5. Generalism
1) In case of adrenocorticotropic insufficiency, be careful after and during the initial administration to avoid water toxicity.
2) Water intake should be limited from 1 hour before to 8 hours after administration of this drug. However, when diagnosing renal function, fluid intake is limited to a maximum of 0.5 L from 1 hour before to 12 hours after administration of this drug. Failure to limit fluid intake may result in fluid retention and/or hyponatremia. (Headache, nausea/vomiting, weight gain, and in severe cases, convulsions)
3) In clinical trials, the incidence of hyponatremia was found to be higher in patients over 65 years of age.
Therefore, it is not recommended to initiate treatment in elderly patients, especially those with diseases that may cause fluid or electrolyte imbalance. The risk of hyponatremia is high in elderly patients, patients with low serum sodium levels, and patients with a high 24-hour cumulative urination volume (more than 2.8-3L). If treatment is to be considered in elderly patients, serum sodium should be measured immediately before treatment and 3 days after the start of treatment, or when the dose is increased and when necessary during administration. If symptoms of water retention and/or hyponatremia (headache, nausea, vomiting, weight gain, convulsions, etc.) appear, medication should be discontinued until the patient fully recovers. When resuming treatment, strict restriction of fluid intake is necessary.
4) To diagnose nocturia in patients with nocturia, the frequency of urination/volume of urination must be recorded for at least 2 days before starting treatment. If the amount of nocturia produced exceeds the functional bladder capacity or exceeds one-third of the 24-hour accumulated urine volume, it is considered nocturia.
5) Medication should be discontinued while suffering from an acute intermittent illness that may cause fluid or/and electrolyte imbalance, such as systemic infection, fever, or gastrointestinal inflammation.
6) This drug has no effect on the ability to drive or operate machinery.
6. Interaction
1) The contractile effect of this drug is very low compared to the antidiuretic effect, but when administering high doses of this drug in combination with other contractiles, the patient must be carefully observed.
2) Since hyponatremic convulsions have been reported due to the combined use of this drug with tricyclic antidepressants and imipramine hydrochloride, monitor serum sodium and plasma osmolality.
3) Chlorpromazine, carbamazepine, clofibrate, clopropamide, indomethacin, and prostaglandin synthase inhibitors may increase the antidiuretic effect and increase the risk of water retention.
4) If this drug is co-administered with systemic and inhaled corticosteroids (hydrocortisone, methylprednisolone, prednisolone, dexamethasone), the risk of hyponatremia may increase.
5) When administered in combination with glibencramide, the antidiuretic effect may be reduced.
6) When administered in combination with oxytocin, it may increase the antidiuretic effect and weaken the uterine blood supply.
7) When administering non-steroidal anti-inflammatory drugs simultaneously, caution is required to avoid hyponatremia, including limiting fluid intake and monitoring serum sodium.
8) When administered concurrently with loperamide, the plasma concentration of desmopressin increases approximately 3-fold, which may increase the risk of water retention/hyponatremia.
9) Co-administration with dimethicone may result in decreased absorption of desmopressin.
10) This drug did not undergo any significant hepatic metabolism in in vitro tests conducted with human microsomes.
Therefore, there appears to be no interaction with drugs that affect liver metabolism (no in vivo studies were conducted).
11) When a standard meal containing 27% fat was eaten at the same time as this drug or one and a half hours before administration, the absorption rate and speed of desmopressin decreased by about 40%. However, no significant effects were observed in terms of pharmacodynamics (urinogenesis or osmotic pressure).
12) Food intake reduces drug absorption, so always take it at the same time as food intake.
Administer medication.
7. Administration to pregnant and lactating women
1) Caution should be exercised in pregnant women as uterine contraction effects may occur in rare cases.
2) In animal reproduction tests, there were no harmful effects on the fetus. Although no harmful effects on the fetus have been reported in the treatment of diabetes insipidus in pregnant women, there is insufficient experience with its use, so it is administered to pregnant women and women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
3) In case of overdose of this drug (300㎍ administered intranasally), a large amount is transferred into breast milk and the safety of administration during lactation has not been established, so it is advisable to discontinue breastfeeding when administering to a nursing mother.
8. Treatment in case of overdose
1) Symptoms: The risk of water retention and hyponatremia increases, and headaches, feeling cold, mouth stings, convulsions, and loss of consciousness may occur.
2) Treatment: Depending on symptoms, reduce the number of doses or dose and limit fluids. There is no specific antidote for this drug, but in case of severe water retention, isotonic or hypertonic saline solution is injected. If water retention is severe (convulsions, loss of consciousness, etc.), administer a diuretic such as furosemide.
11. Data on pharmaceutical equivalence Note 1
A. The test drug Neuritan tablets 0.2 mg (Nexpharm Korea Co., Ltd.) and the control drug Minilin tablets 0.2 mg (Korea Ferring Pharmaceuticals Co., Ltd.) were administered orally once on an empty stomach to 57 healthy adults in a 2×2 crossover test. As a result of measuring blood desmopressin, when the comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the difference in average values was found. The 90% confidence interval was within log 0.8 to log 1.25, proving biological equivalence.
*Table: refer to manual
B. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, comparative dissolution test data were submitted for the test drug Neuritan Tablets 0.1 mg (desmopressin acetate) (Nexpharm Korea Co., Ltd.) with the reference drug Neuritan Tablets 0.2 mg (desmopressin acetate) (Nexpharm Korea Co., Ltd.), and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.
Note 1) This drug was manufactured using the same raw materials as Nexpharm Korea's Neuritan Tablet 0.1 mg (desmopressin acetate) and the entire process was outsourced to Nexpharm Korea using the same manufacturing method.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
1 tablet
- Active ingredients:
Desmopressin acetate (EP) ----- 0.1mg
(0.089mg as desmopressin)
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: magnesium stearate, corn starch, povidone
2. Effectiveness
Treatment of primary enuresis (age 5 or older) and nocturia related to nocturia (limited to adults)
3. Dosage and dosage
Primary enuresis (age 5 or older): Administer 0.2 mg orally as desmopressin acetate at bedtime. If the effect is not sufficient, the dose can be increased up to 0.4mg. The continuation of treatment is determined after stopping administration for at least 1 week after 3 months of administration.
Treatment of nocturia symptoms related to nocturnal polyuria (adults only): Orally administer 0.1 mg of desmopressin acetate at bedtime. If the effect is not sufficient after a week, the dose can be increased to 0.2mg. If the effect continues to be insufficient, the dose can be increased at weekly intervals up to 0.4mg.
If there is no clinical effect within 4 weeks after determining the dose, discontinue administration.
For patients over 65 years of age, it is not recommended to begin treatment with this drug, and for elderly patients requiring treatment, serum sodium levels, etc. should be closely monitored. (Refer to 5. General precautions among the precautions for use)
4. Precautions for use
1. Warning
In the following and elderly people, hyponatremia and water intoxication can cause coma, so to prevent this, be careful to drink just enough water to quench your thirst.
2. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or its ingredients
2) Patients with habitual and psychological polydipsia (if urine volume exceeds 40mL/kg in 24 hours)
3) Patients with dysfunctional heart failure
4) Patients taking diuretics
5) Patients with nephrogenic diabetes insipidus
6) This drug is administered only to patients with normal blood pressure when treating enuresis.
7) Patients with moderate and severe renal failure (creatinine clearance less than 50ml/min)
8) Antidiuretic hormone hypersecretion syndrome (SIADH)
9) Patients diagnosed with hyponatremia
10) This drug contains lactose, so galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
It should not be administered to patients with genetic problems such as (glucose-galactose malabsorption).
3. Administer with caution to the following patients.
1) Patients with circulatory disease accompanied by high blood pressure, severe arteriosclerosis, or coronary thrombosis (this may increase blood pressure and worsen symptoms)
2) Patients with chronic kidney disease
3) Pregnant women or women who may be pregnant
4) Children and elderly people
5) Patients with diseases that cause water and electrolyte imbalance and patients at risk of increased intracranial pressure
6) Patients with diseases related to water and electrolyte imbalance, such as cystic fibrosis (can cause hyponatremia)
7) For patients with urge incontinence, increased urinating frequency or nocturia due to organic causes (e.g. benign prostatic hyperplasia (BPH), urinary tract infection, bladder stones/tumor), polydipsia, and uncontrolled diabetes, the underlying disease should be treated.
4. Adverse reactions
1) In particular, severe water intoxication and hyponatremia accompanied by coma, convulsions, and weight gain may occur in the following and elderly patients.
2) Side effects reported in enuresis patients are as follows: allergic reaction, hyponatremia, emotional disturbance, headache, abdominal pain, nausea, and allergic skin reaction.
3) In clinical trials on patients with nocturia, 35% of patients who reported side effects showed side effects during dose adjustment, and the side effects reported were as follows: hyponatremia, headache, dizziness, peripheral edema, frequent urination, abdominal pain, nausea, dry mouth, and weight gain.
4) Side effects reported from the ingredients of this medicine are as follows: Anaphylaxis
5. Generalism
1) In case of adrenocorticotropic insufficiency, be careful after and during the initial administration to avoid water toxicity.
2) Water intake should be limited from 1 hour before to 8 hours after administration of this drug. However, when diagnosing renal function, fluid intake is limited to a maximum of 0.5 L from 1 hour before to 12 hours after administration of this drug. Failure to limit fluid intake may result in fluid retention and/or hyponatremia. (Headache, nausea/vomiting, weight gain, and in severe cases, convulsions)
3) In clinical trials, the incidence of hyponatremia was found to be higher in patients over 65 years of age.
Therefore, it is not recommended to initiate treatment in elderly patients, especially those with diseases that may cause fluid or electrolyte imbalance. The risk of hyponatremia is high in elderly patients, patients with low serum sodium levels, and patients with a high 24-hour cumulative urination volume (more than 2.8-3L). If treatment is to be considered in elderly patients, serum sodium should be measured immediately before treatment and 3 days after the start of treatment, or when the dose is increased and when necessary during administration. If symptoms of water retention and/or hyponatremia (headache, nausea, vomiting, weight gain, convulsions, etc.) appear, medication should be discontinued until the patient fully recovers. When resuming treatment, strict restriction of fluid intake is necessary.
4) To diagnose nocturia in patients with nocturia, the frequency of urination/volume of urination must be recorded for at least 2 days before starting treatment. If the amount of nocturia produced exceeds the functional bladder capacity or exceeds one-third of the 24-hour accumulated urine volume, it is considered nocturia.
5) Medication should be discontinued while suffering from an acute intermittent illness that may cause fluid or/and electrolyte imbalance, such as systemic infection, fever, or gastrointestinal inflammation.
6) This drug has no effect on the ability to drive or operate machinery.
6. Interaction
1) The contractile effect of this drug is very low compared to the antidiuretic effect, but when administering high doses of this drug in combination with other contractiles, the patient must be carefully observed.
2) Since hyponatremic convulsions have been reported due to the combined use of this drug with tricyclic antidepressants and imipramine hydrochloride, monitor serum sodium and plasma osmolality.
3) Chlorpromazine, carbamazepine, clofibrate, clopropamide, indomethacin, and prostaglandin synthase inhibitors may increase the antidiuretic effect and increase the risk of water retention.
4) If this drug is co-administered with systemic and inhaled corticosteroids (hydrocortisone, methylprednisolone, prednisolone, dexamethasone), the risk of hyponatremia may increase.
5) When administered in combination with glibencramide, the antidiuretic effect may be reduced.
6) When administered in combination with oxytocin, it may increase the antidiuretic effect and weaken the uterine blood supply.
7) When administering non-steroidal anti-inflammatory drugs simultaneously, caution is required to avoid hyponatremia, including limiting fluid intake and monitoring serum sodium.
8) When administered concurrently with loperamide, the plasma concentration of desmopressin increases approximately 3-fold, which may increase the risk of water retention/hyponatremia.
9) Co-administration with dimethicone may result in decreased absorption of desmopressin.
10) This drug did not undergo any significant hepatic metabolism in in vitro tests conducted with human microsomes.
Therefore, there appears to be no interaction with drugs that affect liver metabolism (no in vivo studies were conducted).
11) When a standard meal containing 27% fat was eaten at the same time as this drug or one and a half hours before administration, the absorption rate and speed of desmopressin decreased by about 40%. However, no significant effects were observed in terms of pharmacodynamics (urinogenesis or osmotic pressure).
12) Food intake reduces drug absorption, so always take it at the same time as food intake.
Administer medication.
7. Administration to pregnant and lactating women
1) Caution should be exercised in pregnant women as uterine contraction effects may occur in rare cases.
2) In animal reproduction tests, there were no harmful effects on the fetus. Although no harmful effects on the fetus have been reported in the treatment of diabetes insipidus in pregnant women, there is insufficient experience with its use, so it is administered to pregnant women and women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks.
3) In case of overdose of this drug (300㎍ administered intranasally), a large amount is transferred into breast milk and the safety of administration during lactation has not been established, so it is advisable to discontinue breastfeeding when administering to a nursing mother.
8. Treatment in case of overdose
1) Symptoms: The risk of water retention and hyponatremia increases, and headaches, feeling cold, mouth stings, convulsions, and loss of consciousness may occur.
2) Treatment: Depending on symptoms, reduce the number of doses or dose and limit fluids. There is no specific antidote for this drug, but in case of severe water retention, isotonic or hypertonic saline solution is injected. If water retention is severe (convulsions, loss of consciousness, etc.), administer a diuretic such as furosemide.
11. Data on pharmaceutical equivalence Note 1
A. The test drug Neuritan tablets 0.2 mg (Nexpharm Korea Co., Ltd.) and the control drug Minilin tablets 0.2 mg (Korea Ferring Pharmaceuticals Co., Ltd.) were administered orally once on an empty stomach to 57 healthy adults in a 2×2 crossover test. As a result of measuring blood desmopressin, when the comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the difference in average values was found. The 90% confidence interval was within log 0.8 to log 1.25, proving biological equivalence.
*Table: refer to manual
B. In accordance with Article 7, Paragraph 2 of the Pharmaceutical Equivalence Test Standards, comparative dissolution test data were submitted for the test drug Neuritan Tablets 0.1 mg (desmopressin acetate) (Nexpharm Korea Co., Ltd.) with the reference drug Neuritan Tablets 0.2 mg (desmopressin acetate) (Nexpharm Korea Co., Ltd.), and the dissolution pattern was equivalent to that of the reference drug. Accordingly, bioequivalence was proven with the relevant data.
Note 1) This drug was manufactured using the same raw materials as Nexpharm Korea's Neuritan Tablet 0.1 mg (desmopressin acetate) and the entire process was outsourced to Nexpharm Korea using the same manufacturing method.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 3items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 3 | UrimoQ Tab. 0.1mg | Precautions for use | 2025.12.26 | PDF0039_202002926_Yurimoku Tablet 0.1mg_Precautions for use.pdf |
| 2 | UrimoQ Tab. 0.1mg | Precautions for use | 2024.05.28 | PDF0046_202002926_Yurimoku Tablet 0.1mg_Precautions for use (draft change).pdf |
| 1 | UrimoQ Tab. 0.1mg | Dosage and usage | 2021.06.11 | Desmopressin acetate single agent (content 0.1mg 0.2mg uncoated tablet) Unification adjustment plan (including change comparison table).pdfFile under review |